Ascorbic acid as an adjuvant in the treatment of anemia in patients with Chronic Kidney Disease on hemodialysis: integrative literature review
DOI:
https://doi.org/10.33448/rsd-v11i4.27155Keywords:
Anemia; Hemodyalisis; Ascorbic Acid; Chronic kidney disease.Abstract
Objective: to investigate the scientific evidence in the literature on the effects of Ascorbic Acid on biochemical outcomes such as hemoglobin, ferritin, and transferrin saturation in patients with chronic kidney disease undergoing renal replacement therapy. Methods: This is an integrative literature review study with a qualitative approach. Databases were used; Latin American Literature in Health Sciences (LILACS), Medical Literature and Retrieval System online (Medline), Excerpta Médica dataBASE (EMBASE), Cochrane Library. Eleven studies were included, only clinical trials that used ascorbic acid in hemodialysis patients and analyzed its effects. Results: The findings corroborate the efficacy of Ascorbic Acid as an adjuvant in the treatment of anemia in patients undergoing hemodialysis treatment, since it increases serum hemoglobin and reduces the need for Human Recombinant Erythropoietin. In addition, they depict a reduction in serum ferritin levels and an increase in transferrin saturation, a fact that increases its bioavailability and is useful in functional iron deficiency. Conclusion: Although studies are limited by the small number of participants, short duration of follow-up after the intervention and quality variability, Ascorbic Acid appears to be effective as an adjunct in the control of anemia. Longer-term studies are needed to confirm these results, report adverse events, and determine the impact on long-term outcomes.
References
Agarwal, N., & Prchal, J. T. (2009). Anemia of chronic disease (anemia of inflammation). Acta haematologica, 122(2-3), 103–108. https://doi.org/10.1159/00024379434.
Attallah, N., Osman-Malik, Y., Frinak, S., & Besarab, A. (2006). Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. American journal of kidney diseases: the official journal of the National Kidney Foundation, 47(4), 644–654. https://doi.org/10.1053/j.ajkd.2005.12.025
Candan, F., Gültekin, F., & Candan, F. (2002). Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc-deficient haemodialysis patients. Cell biochemistry and function, 20(2), 95–98. https://doi.org/10.1002/cbf.947
Chan, D., Irish, A., & Dogra, G. (2005). Efficacy, and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology 10(4):336-40. 10.1111/j.1440-1797.2005.00424. x. PMID: 16109077.
Deicher, R., Ziai, F., Bieglmayer, C., Schillinger, M., & Hörl, W. H. (2005). Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. Journal of the American Society of Nephrology: JASN, 16(6), 1811–1818. https://doi.org/10.1681/ASN.2004100850
Descombes, E., Hanck, A. B., & Fellay, G. (1993). Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney international, 43(6), 1319–1328. https://doi.org/10.1038/ki.1993.185
Deved, V., Poyah, P., James, M. T., Tonelli, M., Manns, B. J., Walsh, M., Hemmelgarn, B. R., & Alberta Kidney Disease Network (2009). Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. American journal of kidney diseases: the official journal of the National Kidney Foundation, 54(6), 1089–1097. https://doi.org/10.1053/j.ajkd.2009.06.040
Drüeke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D. (2006); CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071-84.
Ebben, J. P., Gilbertson, D. T., Foley, R. N., & Collins, A. J. (2006). Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clinical journal of the American Society of Nephrology: CJASN, 1(6), 1205–1210. https://doi.org/10.2215/CJN.0111030630
Gafter-Gvili, A., Schechter, A., & Rozen-Zvi, B. (2019). Iron Deficiency Anemia in Chronic Kidney Disease. Acta haematologica, 142(1), 44–50. https://doi.org/10.1159/ 000496492
Gillis, K., Stevens, K. K., Bell, E., Patel, R. K., Jardine, A. G., Morris, S. T. W., Schneider M. P., Delles C., & Mark P. B. (2018). Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease. Clin Kidney J. 11(4) 532-539. 10.1093/ckj/sfx158.
Grotto, H. Z. W. (2008). Metabolismo do ferro: uma revisão sobre os principais mecanismos envolvidos em sua homeostase. Revista Brasileira de Hematologia e Hemoterapia, 30(5), 390-397. < https://doi.org/10.1590/S1516-84842008000500012.
Handelman G. J. (2007). Vitamin C deficiency in dialysis patients--are we perceiving the tip of an iceberg? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 22(2), 328–331. https://doi.org/10.1093/ndt/gfl53435.
Kang, D.W., Ahn, C.Y., Ryu, B.K., Shin, B.C., Chung, J.H., & Kim, H. L. (2012). The effect of intravenous ascorbic acid in hemodialysis patients with normoferritinemic anemia. Kidney Res Clin Pract.31(1):48-53. 10.1016/j.krcp.2012.01.002.
Kawabata, H., Yang, R., Hirama, T., Vuong, P. T., Kawano, S., Gombart, A. F., & Koeffler, H. P. (1999). Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. The Journal of biological chemistry, 274(30), 20826–20832. https://doi.org/10.1074/jbc.274.30.20826
Keven, K., Kutlay, S., Nergizoglu, G., & Ertürk, S. (2003). Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation, 41(6), 1233–1239. https://doi.org/10.1016/s0272-6386(03)00356-1
Kidney Disease: Improving Global Outcomes (KDIGO) (2012). Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter., 2: 308.
Kuragano, T., Yahiro, M., Kida, A., Furuta, M., Nagasawa, Y., Hasuike, Y., Nanami, M., & Nakanishi, T. (2014). Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis. The International journal of artificial organs, 37(12), 865–874. https://doi.org/10.5301/ijao.5000370.
Lin, C. L., Hsu, P. Y., Yang, H. Y., & Huang, C. C. (2003). Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Renal failure, 25(3), 445–453. https://doi.org/10.1081/jdi-120021157
Locatelli, F., Bárány, P., Covic, A., De Francisco, A., Del Vecchio, L., Goldsmith, D., Hörl, W., London, G., Vanholder, R., Van Biesen, W., & ERA-EDTA ERBP Advisory Board (2013). Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 28(6), 1346–1359. https://doi.org/10.1093/ndt/gft033
Locatelli, F., Canaud, B., Eckardt, K. U., Stenvinkel, P., Wanner, C., & Zoccali, C. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 18(7), 1272–1280. https://doi.org/10.1093/ndt/gfg074
Manela-Azulay, M.; Mandarim-de-Lacerda, C. A.; Perez, M. A.; Filgueira, A. L.; Cuzzi, T. (2003) Vitamina C. Anais Brasileiros de Dermatologia 78(3) https://doi.org/10.1590/S0365-05962003000300002.
Oliveira Júnior, W. V., Sabino, A. P., Figueiredo, R. C., & Rios, D. R. A. (2015). Inflamação e má resposta ao uso de eritropoetina na doença renal crônica. Braz. J. Nephrol., 37(2), 255-263.
Palmer, S. C., Saglimbene, V., Mavridis, D., Salanti, G., Craig, J. C., Tonelli, M., Wiebe, N., & Strippoli, G. F. (2014). Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. The Cochrane database of systematic reviews, 2014(12), CD010590. https://doi.org/10.1002/14651858.CD010590.pub2
Pfeffer M. A., Burdmann E. A., Chen C. Y., Cooper M. E., de Zeeuw D., Eckardt K. U.. (2009); TREAT Investigators. A trial of Darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-32. PMID: 19880844 (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012 Sep; 60:390
Pisoni, R. L., Bragg-Gresham, J. L., Young, E. W., Akizawa, T., Asano, Y., Locatelli, F., Bommer, J., Cruz, J. M., Kerr, P. G., Mendelssohn, D. C., Held, P. J., & Port, F. K. (2004). Anemia management and outcomes from twelve countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American journal of kidney diseases: the official journal of the National Kidney Foundation, 44(1), 94–111. https://doi.org/10.1053/j.ajkd.2004.03.023.
Richter, A., Kuhlmann, M. K., Seibert, E., Kotanko, P., Levin, N. W., & Handelman, G. J. (2008). Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 23(6), 2058–2063. https://doi.org/10.1093/ndt/gfn084
Sedighi, O., Makhlough, A., Janbabai, G., Neemi, M. (2013). Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon;5(4):913-917. 10.5812/numonthly.12038
Sezer, S., Ozdemir, F. N., Yakupoglu, U., Arat, Z., Turan, M., & Haberal, M. (2002). Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artificial organs, 26(4), 366–370. https://doi.org/10.1046/j.1525-1594.2002.06888.x
Shahrbanoo K., & Taziki O. (2008). Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl. 2008 Nov;19(6):933-6.
Sing A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., & Wolfson M. (2006); CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
Sirover, W. D., Liu, Y., Logan, A., Hunter, K., Benz, R. L., Prasad, D., Avila, J., Venkatchalam, T., Weisberg, L. S., & Handelman, G. J. (2015). Plasma ascorbic acid concentrations in prevalent patients with end-stage renal disease on hemodialysis. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 25(3), 292–300. https://doi.org/10.1053/j.jrn.2014.09.007.
Sirover, W. D., Siddiqui, A. A., & Benz, R. L. (2008). Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Renal failure, 30(9), 884–889. https://doi.org/10.1080/08860220802353884
Tanaka, M., Komaba, H., & Fukagawa, M. (2018). Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 22(3), 242–245. https://doi.org/10.1111/1744-9987.12685
Tarng, D. C., & Huang, T. P. (1998). A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 13(11), 2867–2872. https://doi.org/10.1093/ndt/13.11.2867.
Tarng, D. C., Wei, Y. H., Huang, T. P., Kuo, B. I., & Yang, W. C. (1999). Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney international, 55(6), 2477–2486. https://doi.org/10.1046/j.1523-1755.1999.00479.x
Valderrábano F. (2002). Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 17 Suppl 1, 13–18. https://doi.org/10.1093/ndt/17.suppl_1.13
Wang, S., Eide, T. C., Sogn, E. M., Berg, K. J., & Sund, R. B. (1999). Plasma ascorbic acid in patients undergoing chronic haemodialysis. European journal of clinical pharmacology, 55(7), 527–532. https://doi.org/10.1007/s002280050668
Washio, K., Inagaki, M., Tsuji, M., Morio, Y., Akiyama, S., Gotoh, H., Gotoh, T., Gotoh, Y., & Oguchi, K. (2008). Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker. Nephron. Clinical practice, 109(2), c49–c54. https://doi.org/10.1159/000137628
Whittemore R., & Knafl K. (2005). The integrative review: updated methodology. J Adv Nurs. 52(5):546-53.
Zhang, K., Liu, L., Cheng, X., Dong, J., Geng, Q., & Zuo, L. (2011). Low levels of vitamin C in dialysis patients are associated with decreased prealbumin and increased C-reactive protein. BMC nephrology, 12, 18. https://doi.org/10.1186/1471-2369-12-18
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Kleber Luiz da Fonseca Azevedo; Eudes Euler de Lucena Souza; Micássio Fernandes Andrade
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
